Page last updated: 2024-08-24

tolafentrine and rolipram

tolafentrine has been researched along with rolipram in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (66.67)18.2507
2000's1 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hatzelmann, A; Schudt, C; Tenor, H1
Enke, B; Ghofrani, HA; Grimminger, F; Schermuly, RT; Schudt, C; Seeger, W; Walmrath, D; Weissmann, N1
Ghofrani, HA; Grimminger, F; Roehl, A; Schermuly, RT; Schudt, C; Seeger, W; Tenor, H; Walmrath, D; Weissmann, N1

Other Studies

3 other study(ies) available for tolafentrine and rolipram

ArticleYear
Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.
    British journal of pharmacology, 1995, Volume: 114, Issue:4

    Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Antagonists; Benzamides; Blood Proteins; Cell Separation; Complement C5a; Cyclic Nucleotide Phosphodiesterases, Type 4; Electromagnetic Fields; Eosinophil Granule Proteins; Eosinophil-Derived Neurotoxin; Eosinophils; Humans; Inflammation Mediators; Luminescent Measurements; Naphthyridines; Neurotoxins; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyridazines; Pyridines; Pyrrolidinones; Ribonuclease, Pancreatic; Ribonucleases; Rolipram; Theophylline

1995
Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension.
    American journal of respiratory and critical care medicine, 1999, Volume: 160, Issue:5 Pt 1

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Administration, Inhalation; Aerosols; Animals; Antihypertensive Agents; Blood Pressure; Cardiac Output; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epoprostenol; Hypertension, Pulmonary; Naphthyridines; Phosphodiesterase Inhibitors; Pulmonary Circulation; Purinones; Pyridazines; Rabbits; Rolipram; Vasoconstrictor Agents; Vasodilation

1999
Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange.
    The Journal of pharmacology and experimental therapeutics, 2000, Volume: 292, Issue:2

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aerosols; Animals; Antihypertensive Agents; Cyclic AMP; Dose-Response Relationship, Drug; Drug Interactions; Edema; Epoprostenol; Female; Hemodynamics; Hypertension, Pulmonary; Lung; Male; Naphthyridines; Perfusion; Phosphodiesterase Inhibitors; Pyridazines; Rabbits; Rolipram; Time Factors; Vasoconstrictor Agents

2000